Revelation Biosciences (OTCMKTS:REVB – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Saturday, Zacks.com reports. The brokerage presently has a $0.75 price objective on the stock. Zacks Investment Research‘s price objective would suggest a potential upside of 32.28% from the stock’s previous close.
According to Zacks, “Revelation Biosciences Inc. is a clinical-stage life sciences company. It focused on the development of immunologic-based therapies for the prevention and treatment of disease. The company’s product pipeline includes REVTx-99, REVTx-200 and REVDx-501. Revelation Biosciences Inc., formerly known as Petra Acquisition Inc., is based in NEW YORK. “
Separately, Roth Capital started coverage on Revelation Biosciences in a research report on Thursday, February 17th. They issued a “buy” rating and a $12.00 price target for the company.
Revelation Biosciences (OTCMKTS:REVB – Get Rating) last issued its earnings results on Monday, May 16th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.25). On average, equities research analysts anticipate that Revelation Biosciences will post -0.57 EPS for the current year.
In related news, Director George F. Tidmarsh purchased 20,000 shares of the company’s stock in a transaction that occurred on Friday, February 25th. The stock was bought at an average price of $1.60 per share, for a total transaction of $32,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 19.90% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in REVB. Ergoteles LLC bought a new position in Revelation Biosciences in the first quarter worth approximately $25,000. Marshall Wace LLP bought a new position in Revelation Biosciences in the fourth quarter worth approximately $508,000. Finally, Monashee Investment Management LLC acquired a new position in shares of Revelation Biosciences during the first quarter worth $932,000. Hedge funds and other institutional investors own 73.36% of the company’s stock.
Revelation Biosciences Company Profile (Get Rating)
Revelation Biosciences, Inc, a clinical -stage biopharmaceutical company, focuses on the development or commercialization of innate immune system therapeutics and diagnostics. The company's lead therapeutic candidate is REVTx-99, an anti -viral nasal drop for the prevention or treatment of respiratory viral infections, as well as for the prevention or treatment of nasal congestion due to allergies or chronic rhinosinusitis.
- Get a free copy of the StockNews.com research report on Revelation Biosciences (REVB)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Will John Deere’s Earnings Help to Calm the Markets?
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Lowe’s Companies Has Not Bottomed
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Revelation Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revelation Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.